# To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin

> **NCT05162014** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 494679 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** empagliflozin
- **DRUG:** Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents

## Key facts

- **NCT ID:** NCT05162014
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-20
- **Primary completion:** 2022-09-12
- **Final completion:** 2022-09-12
- **Target enrollment:** 494679 (ACTUAL)
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162014, "To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05162014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*